Overview

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate